IL154089A0 - Peptide selection method - Google Patents

Peptide selection method

Info

Publication number
IL154089A0
IL154089A0 IL15408901A IL15408901A IL154089A0 IL 154089 A0 IL154089 A0 IL 154089A0 IL 15408901 A IL15408901 A IL 15408901A IL 15408901 A IL15408901 A IL 15408901A IL 154089 A0 IL154089 A0 IL 154089A0
Authority
IL
Israel
Prior art keywords
selection method
peptide
peptide selection
mbp
peptides
Prior art date
Application number
IL15408901A
Other languages
English (en)
Original Assignee
Univ Bristol
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26244875&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL154089(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0020618A external-priority patent/GB0020618D0/en
Priority claimed from GB0114547A external-priority patent/GB0114547D0/en
Application filed by Univ Bristol filed Critical Univ Bristol
Publication of IL154089A0 publication Critical patent/IL154089A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Rehabilitation Therapy (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
IL15408901A 2000-08-21 2001-08-17 Peptide selection method IL154089A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0020618A GB0020618D0 (en) 2000-08-21 2000-08-21 Peptide selection method
GB0114547A GB0114547D0 (en) 2001-06-14 2001-06-14 Peptide selection method
PCT/GB2001/003702 WO2002016410A2 (en) 2000-08-21 2001-08-17 Peptide selection method

Publications (1)

Publication Number Publication Date
IL154089A0 true IL154089A0 (en) 2003-07-31

Family

ID=26244875

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15408901A IL154089A0 (en) 2000-08-21 2001-08-17 Peptide selection method

Country Status (25)

Country Link
US (4) US20030191063A1 (xx)
EP (3) EP1918298B1 (xx)
JP (1) JP5431628B2 (xx)
KR (1) KR20030062321A (xx)
CN (4) CN1469883A (xx)
AT (2) ATE483729T1 (xx)
AU (2) AU7863701A (xx)
BR (2) BRPI0113400B1 (xx)
CA (1) CA2420949C (xx)
CY (3) CY1108558T1 (xx)
CZ (1) CZ307202B6 (xx)
DE (2) DE60143234D1 (xx)
DK (3) DK1731912T3 (xx)
ES (3) ES2353347T3 (xx)
HK (3) HK1052359B (xx)
HU (3) HU229377B1 (xx)
IL (1) IL154089A0 (xx)
MX (1) MXPA03001606A (xx)
NO (2) NO330535B1 (xx)
NZ (1) NZ523841A (xx)
PH (1) PH12013500208A1 (xx)
PL (4) PL217929B1 (xx)
PT (3) PT1311542E (xx)
SI (3) SI1918298T1 (xx)
WO (1) WO2002016410A2 (xx)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU229377B1 (hu) 2000-08-21 2013-11-28 Apitope Technology Bristol Ltd Tolerogén humán peptidek
GB0202399D0 (en) 2002-02-01 2002-03-20 Univ Bristol Peptide
PL2420833T3 (pl) * 2006-05-05 2016-03-31 Opexa Therapeutics Szczepionka z komórek T
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
SI2190473T1 (sl) 2007-08-15 2013-05-31 Circassia Limited Peptid z zmanjšano tvorbo dimerov
MX2010004698A (es) * 2007-10-31 2010-05-13 Apitope Technology Bristol Ltd Composicion.
GB0723712D0 (en) * 2007-12-04 2008-01-16 Apitope Technology Bristol Ltd Peptides
ITMI20080508A1 (it) * 2008-03-27 2009-09-28 Istituto Nazionale Di Genetica Molecolare Cellule ematopoietiche esprimenti la proteina krtcap3 e i leganti per la proteina krtcap3
ITMI20080865A1 (it) * 2008-05-13 2009-11-14 Istituto Naz Di Genetica Molecolare Ingm Cellule ematopoietiche esprimenti la proteina susd3 e i leganti per la proteina susd3
US9085798B2 (en) 2009-04-30 2015-07-21 Prognosys Biosciences, Inc. Nucleic acid constructs and methods of use
GB0908515D0 (en) * 2009-05-18 2009-06-24 Apitope Technology Bristol Ltd Peptide
EP2488196B1 (en) 2009-10-12 2015-12-16 LIFEBio Laboratories LLC Composition for treatment of multiple sclerosis
RU2448685C2 (ru) * 2009-11-30 2012-04-27 Российская Федерация в лице Министерства промышленности и торговли Российской Федерации Липосомы, содержащие олигопептиды - фрагменты основного белка миелина, фармацевтическая композиция и способ лечения рассеянного склероза
US20190300945A1 (en) 2010-04-05 2019-10-03 Prognosys Biosciences, Inc. Spatially Encoded Biological Assays
US10787701B2 (en) 2010-04-05 2020-09-29 Prognosys Biosciences, Inc. Spatially encoded biological assays
KR101866401B1 (ko) 2010-04-05 2018-06-11 프로그노시스 바이오사이언스, 인코포레이티드 공간적으로 엔코딩된 생물학적 검정
KR200457779Y1 (ko) * 2010-06-23 2012-01-06 이준혁 샤프펜슬
EP3150750B1 (en) 2011-04-08 2018-12-26 Prognosys Biosciences, Inc. Peptide constructs and assay systems
GB201106254D0 (en) 2011-04-13 2011-05-25 Frisen Jonas Method and product
PL397623A1 (pl) * 2011-12-30 2013-07-08 Napco S. Ar.L. Preparat poprawiajacy pamiec oraz uczenie sie, sposób jego wytwarzania, srodek farmaceutyczny, dodatek zywieniowy oraz jego zastosowanie
EP2909337B1 (en) 2012-10-17 2019-01-09 Spatial Transcriptomics AB Methods and product for optimising localised or spatial detection of gene expression in a tissue sample
DK2917232T3 (en) 2012-11-12 2017-06-12 Apitope Int Nv FACTOR VIII DERIVATIVE PEPTIDES TO USE FOR TREATMENT OF HAEMOPHYL A
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
EP2972366B1 (en) 2013-03-15 2020-06-17 Prognosys Biosciences, Inc. Methods for detecting peptide/mhc/tcr binding
LT3013983T (lt) 2013-06-25 2023-05-10 Prognosys Biosciences, Inc. Erdviniai koduoti biologiniai tyrimai, naudojant mikrofluidinį įrenginį
GB201314052D0 (en) 2013-08-06 2013-09-18 Apitope Int Nv Peptides
US10288608B2 (en) 2013-11-08 2019-05-14 Prognosys Biosciences, Inc. Polynucleotide conjugates and methods for analyte detection
KR101503341B1 (ko) 2014-03-12 2015-03-18 국립암센터 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
US10646589B2 (en) * 2014-12-24 2020-05-12 Apitope International Nv Thyroid stimulating hormone receptor peptides and uses thereof
EP4321627A3 (en) 2015-04-10 2024-04-17 10x Genomics Sweden AB Spatially distinguished, multiplex nucleic acid analysis of biological specimens
GB201700095D0 (en) * 2017-01-04 2017-02-22 Apitope Int Nv Composition
EP3565585A1 (en) * 2017-01-04 2019-11-13 Apitope International NV Therapeutic method using tolerogenic peptides
ES2981555T3 (es) 2017-01-04 2024-10-09 Worg Pharmaceuticals Zhejiang Co Ltd Péptidos de S-arrestina y usos terapéuticos de los mismos
EP3523332B1 (en) 2017-01-06 2021-12-29 Eutilex Co., Ltd. Anti-human 4-1 bb antibodies and use thereof
GB201909774D0 (en) 2019-07-08 2019-08-21 Apitope Tech Bristol Limited Method
RU2761617C2 (ru) * 2019-10-04 2021-12-13 Жаудат Гафурович Умеров Комплекс липидов миелина центральной и периферической нервной системы животных для лечения и профилактики нейродегенеративных демиелинизирующих нарушений и способы его применения
GB201919222D0 (en) 2019-12-23 2020-02-05 Apitope Int Nv Composition
US20210190770A1 (en) 2019-12-23 2021-06-24 10X Genomics, Inc. Compositions and methods for using fixed biological samples in partition-based assays
TR201922305A2 (tr) * 2019-12-30 2021-07-26 T C Erciyes Ueniversitesi Multi̇pl skleroz (ms) hastaliğinda beta-kazomorfi̇n pepti̇tleri̇ni̇n kullanilmasi
US11702693B2 (en) 2020-01-21 2023-07-18 10X Genomics, Inc. Methods for printing cells and generating arrays of barcoded cells
US11732299B2 (en) 2020-01-21 2023-08-22 10X Genomics, Inc. Spatial assays with perturbed cells
US11835462B2 (en) 2020-02-11 2023-12-05 10X Genomics, Inc. Methods and compositions for partitioning a biological sample
US11926863B1 (en) 2020-02-27 2024-03-12 10X Genomics, Inc. Solid state single cell method for analyzing fixed biological cells
EP4146190A2 (en) 2020-05-06 2023-03-15 Imcyse SA Combination treatment for fumarate-related diseases
EP4153775B1 (en) 2020-05-22 2024-07-24 10X Genomics, Inc. Simultaneous spatio-temporal measurement of gene expression and cellular activity

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1327162C (en) 1987-04-09 1994-02-22 Board Of Trustees Of The Leland Stanford Junior University (The) Method for prophylactically treating an individual for an autoimmune disease
CA1336954C (en) 1987-06-24 1995-09-12 Howard L. Weiner Treatment of autoimmune diseases by oral administration of autoantigens
US5260422A (en) * 1988-06-23 1993-11-09 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
IL97709A (en) * 1990-03-30 2005-05-17 Brigham & Womens Hospital Use of an mbp peptide for the preparation of a medicament for the treatment of multiple sclerosis
US6036957A (en) * 1990-03-30 2000-03-14 Autoimmune, Inc. Suppression of T-cell proliferation using peptide fragments of myelin basic protein
US5593698A (en) 1990-10-31 1997-01-14 Autoimmune, Inc. Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides
US5817629A (en) * 1991-10-22 1998-10-06 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US5989565A (en) 1993-01-29 1999-11-23 University Of Pittsburgh Elution and identification of T cell epitopes from viable cells
HUT76099A (en) * 1994-05-10 1997-06-30 Immulogic Pharma Corp Compositions and treatment for multiple sclerosis
AU7242994A (en) 1994-05-20 1995-12-18 United States Of America, As Represented By The Secretary Of The Army, The Model for testing immunogenicity of peptides
US6379670B1 (en) * 1994-11-18 2002-04-30 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
US6251396B1 (en) * 1994-11-18 2001-06-26 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
US6329499B1 (en) * 1994-11-18 2001-12-11 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein
IL117976A0 (en) * 1995-04-20 1996-08-04 Brigham & Womens Hospital Modulation of cytokine patterns of human autoreactive t-cell clones
AU738649B2 (en) * 1996-04-26 2001-09-20 Rijksuniversiteit Te Leiden Methods for selecting and producing T cell peptide epitopes and vaccines incorporating said selected epitopes
EP0849275A1 (en) * 1996-09-26 1998-06-24 Rijksuniversiteit te Leiden Mannosylated peptides
CA2331378A1 (en) 1998-06-12 1999-12-16 Sloan-Kettering Institute For Cancer Research Vaccination strategy to prevent and treat cancers
MY129566A (en) * 1999-01-19 2007-04-30 Nestle Sa A hypoallergenic composition containing tolerogenic peptides inducing oral tolerance
HU229377B1 (hu) * 2000-08-21 2013-11-28 Apitope Technology Bristol Ltd Tolerogén humán peptidek
GB0202399D0 (en) 2002-02-01 2002-03-20 Univ Bristol Peptide
US8314290B2 (en) 2004-12-21 2012-11-20 Monsanto Technology Llc Temporal regulation of gene expression by MicroRNAs
MX2010004698A (es) 2007-10-31 2010-05-13 Apitope Technology Bristol Ltd Composicion.
GB0723712D0 (en) 2007-12-04 2008-01-16 Apitope Technology Bristol Ltd Peptides

Also Published As

Publication number Publication date
CY1111079T1 (el) 2015-06-11
DE60134862D1 (de) 2008-08-28
NO337988B1 (no) 2016-07-18
WO2002016410A2 (en) 2002-02-28
PH12013500208B1 (en) 2015-04-20
PT1311542E (pt) 2008-10-03
SI1731912T1 (sl) 2014-05-30
BRPI0113400B1 (pt) 2018-05-15
US20180311328A1 (en) 2018-11-01
CN102764425A (zh) 2012-11-07
ES2353347T3 (es) 2011-03-01
PH12013500208A1 (en) 2015-04-20
US20130156798A1 (en) 2013-06-20
EP1731912A3 (en) 2006-12-27
CA2420949C (en) 2012-01-03
DK1918298T3 (da) 2010-11-29
US8961986B2 (en) 2015-02-24
CN1469883A (zh) 2004-01-21
SI1311542T1 (sl) 2009-02-28
CN102784385B (zh) 2015-11-25
HK1178793A1 (en) 2013-09-19
ATE483729T1 (de) 2010-10-15
CN102784385A (zh) 2012-11-21
NO20030790D0 (no) 2003-02-19
MXPA03001606A (es) 2004-11-01
NO20030790L (no) 2003-04-22
SI1918298T1 (sl) 2011-01-31
CA2420949A1 (en) 2002-02-28
NO20101441L (no) 2003-04-22
CN102764425B (zh) 2015-11-25
DK1731912T3 (da) 2014-01-06
CN101633689B (zh) 2013-09-04
DK1311542T3 (da) 2008-11-10
JP5431628B2 (ja) 2014-03-05
AU2001278637B2 (en) 2006-05-25
KR20030062321A (ko) 2003-07-23
PL215145B1 (pl) 2013-10-31
JP2004506921A (ja) 2004-03-04
CY1108558T1 (el) 2014-04-09
CY1114808T1 (el) 2016-12-14
HU229377B1 (hu) 2013-11-28
HUP0300814A3 (en) 2005-11-28
US8343500B2 (en) 2013-01-01
NZ523841A (en) 2004-07-30
EP1918298A3 (en) 2008-05-28
CN101633689A (zh) 2010-01-27
ES2439899T3 (es) 2014-01-27
AU7863701A (en) 2002-03-04
NO330535B1 (no) 2011-05-09
PT1731912E (pt) 2013-12-17
US20030191063A1 (en) 2003-10-09
PT1918298E (pt) 2010-12-09
PL399137A1 (pl) 2012-07-30
CZ307202B6 (cs) 2018-03-21
HK1052359A1 (en) 2003-09-11
WO2002016410A3 (en) 2002-09-12
HK1178437A1 (en) 2013-09-13
PL213585B1 (pl) 2013-03-29
BR0113400A (pt) 2003-07-08
HUP0300814A2 (hu) 2003-10-28
PL217929B1 (pl) 2014-09-30
HU230233B1 (hu) 2015-10-28
ES2310558T3 (es) 2009-01-16
EP1311542B1 (en) 2008-07-16
PL364048A1 (en) 2004-12-13
EP1918298B1 (en) 2010-10-06
ATE401343T1 (de) 2008-08-15
HK1052359B (zh) 2008-11-14
PL215187B1 (pl) 2013-11-29
EP1731912A2 (en) 2006-12-13
DE60143234D1 (de) 2010-11-18
HU229489B1 (hu) 2014-01-28
EP1918298A2 (en) 2008-05-07
EP1311542A2 (en) 2003-05-21
PL399138A1 (pl) 2012-07-30
US20080200368A1 (en) 2008-08-21
EP1731912B1 (en) 2013-09-25

Similar Documents

Publication Publication Date Title
HK1178793A1 (en) Peptide selection method
WO1998026747A3 (en) Superantigen based methods and compositions for treatment of diseases
AU2002229510A1 (en) Combined use of factor vii polypeptides and factor viii polypeptides
AUPN568095A0 (en) Anti-Galalpha(1,3)Gal antibody binding peptides
AR245778A1 (es) Secuencia de nucleotido que codifica una proteina de membrana exterior de neisseria meningitis y uso de dicha proteina en preparaciones de vacuna
CY1110862T1 (el) Πεπτιδια που προκαλουν ανοσολογικη ανοχη απο βασικη πρωτεϊνη της μυελινης
HK1063188A1 (en) Peptide for the diagnosis and therapy of alzeimer's disease
NZ515936A (en) Antigenic Neisserial peptides
IS7296A (is) Bóluefni og aðferð við meðhöndlun á hreyfitaugungahrörnun
WO1999057241A3 (en) Myelin basic protein peptides and uses thereof
WO2004069204A3 (en) Immunogenic acute phase protein-antigenic molecule complexes and fusion proteins
WO2004080387A3 (en) Immunogenic cd19 ligand-antigenic molecule complexes and fusion proteins